CYP3A4 and breast cancer: In this sense, a previous study has shown that, in breast cancer, the activation of AhR can modulate the response to antitumor treatment with the antibiotic doxorubicin by an increase in the protein expression of cytochrome P450 (CYP) 2D6, CYP2C8 and CYP3A4 [33], but there is lack of evidence about a similar effect of HCB on PX antitumor treatment in TNBC.